Sarah Gordon Wild has a BSc (Hons) from Aberdeen University and an MSc from Imperial College, University of London. She was a Biotechnology Investment Analyst in the City from 1983 to 1986. She then moved to New York City where she worked as a biotechnology and healthcare analyst for more than 17 years.  She worked as an analyst and then portfolio manager at Lone Pine Capital LLC from 1998 to 2003.  Sarah has served on the Boards of Immunomedics and Praecis Pharmaceuticals and continues to serve as an Offshore Fund Board member for Lone Pine Capital.

Since her return to the UK in 2003 she has run SGW Research Ltd on a part time basis, investing a portion of her own assets in healthcare companies. She also serves on the boards of Oxford Nanopore and Evox Therapeutics.  Sarah is a keen rider and travels with her husband Jim.  Her daughters, Victoria and Emma, loved life at Leweston and their experience provided a compelling reason to actively support the school.